US EditionWegovy-maker Novo Nordisk to cut 9,000 jobs in restructuring
- Novo Nordisk announced on September 10, 2025, a company-wide restructuring to cut 9,000 jobs globally and simplify its organisation.
- The restructuring follows a profit warning, slowing US sales of Wegovy and Ozempic, and rising competition from Eli Lilly in obesity and diabetes markets.
- About 5,000 of the layoffs will occur in Denmark, representing roughly 11.5% of Novo Nordisk’s 78,400-strong workforce, reallocating resources to growth areas.
- The company expects annual savings of approximately 8 billion Danish crowns , with CEO Mike Doustdar stating, “Our company must evolve as well.”
- The overhaul aims to improve decision speed and prioritize investments, reflecting confidence despite lowering operating profit growth to 4-10% this year.
171 Articles
171 Articles
Ozempic Creator Novo Nordisk to Slash 9,000 Jobs by End of 2026
Denmark-based Novo Nordisk, the manufacturer of the popular Ozempic diabetes medication, announced on Sept. 10 that it plans to reduce its global workforce by 9,000 employees by the end of 2026 amid intensifying competition in the obesity market, particularly in the United States. In a company statement, Novo Nordisk said the reduction is needed to increase speed and redirect resources to more growth opportunities within the diabetes and obesity…
The Danish pharmaceutical company Novo Nordisk, manufacturer of the weight loss syringes Ozempic and Wegovy, wants to reduce about 9,000 jobs worldwide.
Ozempic maker Novo Nordisk to axe 9,000 jobs in global shake-up
COPENHAGEN: Danish pharmaceutical giant Novo Nordisk announced Wednesday it would cut 11 per cent of its workforce, as the maker of Ozempic and Wegovy faces rising competition for its anti-obesity treatments. © New Straits Times Press (M) Bhd
The Times of Northwest Indiana
Novo Nordisk, maker of Wegovy and Ozempic, to cut 9,000 jobs
The Danish pharmaceutical company said it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company's focus on growth opportunities in obesity and diabetes medications.
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
